Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Fortrea Holdings Inc. (FTRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: FTRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $6.84
1 Year Target Price $6.84
| 0 | Strong Buy |
| 1 | Buy |
| 10 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.34% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 456.32M USD | Price to earnings Ratio - | 1Y Target Price 6.84 |
Price to earnings Ratio - | 1Y Target Price 6.84 | ||
Volume (30-day avg) 12 | Beta 1.6 | 52 Weeks Range 3.97 - 28.41 | Updated Date 07/10/2025 |
52 Weeks Range 3.97 - 28.41 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -29.43% | Operating Margin (TTM) -3.81% |
Management Effectiveness
Return on Assets (TTM) -1.74% | Return on Equity (TTM) -61.58% |
Valuation
Trailing PE - | Forward PE 29.41 | Enterprise Value 1641023197 | Price to Sales(TTM) 0.17 |
Enterprise Value 1641023197 | Price to Sales(TTM) 0.17 | ||
Enterprise Value to Revenue 0.61 | Enterprise Value to EBITDA 92.35 | Shares Outstanding 90540304 | Shares Floating 85353265 |
Shares Outstanding 90540304 | Shares Floating 85353265 | ||
Percent Insiders 0.4 | Percent Institutions 101.9 |
Upturn AI SWOT
Fortrea Holdings Inc.
Company Overview
History and Background
Fortrea Holdings Inc. was spun off from Labcorp (LH) in July 2023. It focuses on providing clinical development and commercialization solutions to the biopharmaceutical and healthcare industries.
Core Business Areas
- Clinical Development: Provides comprehensive clinical trial management services, including Phase I-IV studies, data management, biostatistics, and medical writing.
- Commercialization: Offers commercial strategy consulting, market access solutions, and medical affairs support to help biopharmaceutical companies bring their products to market.
Leadership and Structure
Raymond F. Huml is the CEO of Fortrea. The company operates with a functional structure, organized around its key service areas.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: Comprehensive services for managing clinical trials from Phase I to Phase IV. Market share is evolving post-spinoff, estimated ~5-7% of CRO market. Competitors include IQVIA, ICON, and PPD (Thermo Fisher Scientific).
- Commercialization Solutions: Strategic consulting and support for biopharmaceutical companies launching and marketing their products. Market share is smaller, highly fragmented. Competitors include Syneos Health, EVERSANA, and numerous specialized consultancies.
Market Dynamics
Industry Overview
The clinical research organization (CRO) market is experiencing growth driven by increasing R&D spending in the biopharmaceutical industry, the rising complexity of clinical trials, and the need for specialized expertise.
Positioning
Fortrea is a mid-sized CRO focused on providing integrated clinical development and commercialization solutions. Its competitive advantage lies in its ability to offer a comprehensive suite of services across the drug development lifecycle.
Total Addressable Market (TAM)
The global CRO market is estimated at approximately $75-85 billion. Fortrea is positioned to capture a share of this market by offering comprehensive, integrated solutions.
Upturn SWOT Analysis
Strengths
- Comprehensive service offering
- Strong industry expertise
- Established relationships with biopharmaceutical companies
- Experienced leadership team
- Focus on both clinical and commercial phases
Weaknesses
- Relatively new independent entity
- Smaller scale compared to larger CROs like IQVIA
- Brand recognition still developing
- Integration challenges post-spinoff
- High dependence on key client relationships
Opportunities
- Increasing demand for CRO services
- Growth in biopharmaceutical R&D spending
- Expansion into emerging markets
- Adoption of new technologies (e.g., AI) in clinical trials
- Strategic partnerships and acquisitions
Threats
- Intense competition in the CRO market
- Economic downturn impacting R&D spending
- Regulatory changes affecting clinical trials
- Pricing pressures from biopharmaceutical companies
- Loss of key personnel
Competitors and Market Share
Key Competitors
- IQVIA (IQV)
- Thermo Fisher Scientific (TMO) (PPD is a part of this)
- ICON (ICLR)
- Syneos Health (SYNH)
Competitive Landscape
Fortrea is competing in a crowded market against larger, more established CROs. It aims to differentiate itself through its integrated service offerings and specialized expertise, but it needs to overcome the brand recognition of its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to Labcorp's previous clinical development segment. Future growth is expected to be driven by increasing demand for CRO services.
Future Projections: Analyst estimates for future growth will be available as the company releases its own forecasts and analyst coverage increases.
Recent Initiatives: Recent initiatives include establishing the company as an independent brand and focusing on strategic partnerships to expand its service offerings.
Summary
Fortrea, a recent spin-off from Labcorp, is a mid-sized CRO operating in a growing market. Its comprehensive services offer potential for growth, but it faces competition from established players. Its success depends on building its brand, executing its strategic initiatives, and navigating the evolving regulatory landscape and economical changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- Labcorp filings (prior to spin-off)
- Industry reports
- Analyst estimates
Disclaimers:
Data and analysis are based on available information and estimates, which are subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortrea Holdings Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2023-07-03 | Interim CEO, Chairman of the Board & Lead Independent Director Mr. Peter M. Neupert | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15000 | Website https://www.fortrea.com |
Full time employees 15000 | Website https://www.fortrea.com | ||
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.